Beacon Equity Issues Technical Trading Overview for NexMed Inc.

DALLAS, Aug. 31, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The investment report on NexMed Inc. (Nasdaq:NEXM) should be of particular interest to other biotechnologies companies: Adamis Pharm. Corp. (OTCBB:ADMP), Pfizer Inc. (NYSE:PFE), Eli Lilly & Co. (NYSE:LLY) and Vivus Inc. (Nasdaq:VVUS).

It is available at: http://www.beaconequity.com/i/NEXM

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

NexMed Inc. (NEXM) is a biotechnology company engaged in the development of late-stage terbinafine for the treatment of onychomycosis, or erectile dysfunction. The Company also is in phase II for its alprostadil, a drug therapy for the treatment of female sexual arousal disorder and psoriasis.

In the report, the analyst notes:

"The market's leading drug therapies include Viagra, Levitra and Cialis, with Viagra as the most recognized and popular drug among the three. Data compiled by market research firm, Visiongain, suggest that Cialis and Levitra have gained wider recognition and popularity since 2007 and will take further market share from Pfizer.

"The market for alternative drug therapies for the treatment of ED changed following an FDA alert in July 2005 that non-arteritic anterior ischemic optic neuropathy (NAIPON) was reported in 43 cases of varying degrees of vision loss, including blindness, following the use of erectile dysfunction drugs. Updated labeling guidelines were instituted by the FDA regarding these PDE-5 class drugs which included warnings of vision loss. The FDA announcement came on the heels of physicians' concerns regarding cardiovascular risks surrounding the use of the drugs, later confirmed by the FDA."

To read the entire report visit: http://www.beaconequity.com/i/NEXM

See what investors are saying about these stocks at: http://www.stockhideout.com/

BeaconEquity.com is one of the industry's largest small-cap report and small-cap research providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

CONTACT:  Beacon Equity Research
          Jeff Bishop
          (469)-252-3505
          press@beaconequity.com